Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cocrystal Pharma Inc (COCP) just unveiled an announcement.
Cocrystal Pharma, Inc. has released an update on the progress of its promising compound, CDI-42344, which is currently in clinical development as a treatment and preventive measure for influenza A. The announcement has triggered interest among investors, as it marks a significant step in the company’s efforts to combat this common and challenging illness.
Find detailed analytics on COCP stock on TipRanks’ Stock Analysis page.